Literature DB >> 25983318

Mexican consensus on the diagnosis and management of hepatitis C infection.

Juan Francisco Sánchez-Ávila1, Margarita Dehesa-Violante2, Nahum Méndez-Sánchez3, Francisco Bosques-Padilla4, Mauricio Castillo-Barradas5, Graciela Castro-Narro6, Laura Cisneros-Garza7, Ruby Ann Chirino-Sprung8, Ignacio García-Juarez9, Ma Saraí Gonzalez-Huezo10, René Malé-Velazquez11, Rosalba Moreno-Alcántar12, Linda Muñoz-Espinoza13, Mayra Ramos-Gómez14, Ma Teresa Rizo-Robles15, Ricardo Sandoval-Salas16, Juan Sierra-Madero17, María Del Rocío Torres-Ibarra18, Rodrigo Vazquez-Frias19, Enrique Wolpert-Barraza20.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25983318

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN： 1665-2681            Impact factor:   2.400


× No keyword cloud information.
  2 in total

Review 1.  Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals.

Authors:  Julieta Trinks; Mariela Caputo; María L Hulaniuk; Daniel Corach; Diego Flichman
Journal:  Pharmgenomics Pers Med       Date:  2017-03-28

2.  Effectiveness, tolerability and safety of Direct Acting Antivirals in Mexican individuals with Hepatitis C virus genotype-1 and previous pegylated interferon and ribavirin therapy.

Authors:  Daniel Melendez-Mena; Miguel Angel Mendoza-Torres; Virginia Sedeño-Monge; Víctor Hugo García Y García; Elain Rivera-García; Laura Sánchez-Reza; María Del Carmen Baxin Domínguez; Belinda Guzmán-Flores; Ygnacio Martinez-Laguna; José Manuel Coronel Espinoza; Iván Galindo-Santiago; Juan Carlos Flores-Alonso; Verónica Vallejo-Ruiz; Paulina Cortes-Hernandez; Julio Reyes-Leyva; Francisca Sosa-Jurado; Gerardo Santos-López
Journal:  PeerJ       Date:  2021-09-17       Impact factor: 2.984
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.